State plans for containment of pandemic influenza.
Much recent attention, public, governmental, and academic, has been focused on the possibility of an influenza pandemic, possibly arising from a mutated or genetically reassorted strain of the currently circulating avian influenza virus (H5N1). In the United States, state and local health departments are primarily responsible for detecting an outbreak and implementing the public health response. Accordingly, individual states and the US Department of Health and Human Services (HHS) have each recently released pandemic influenza plans and guidelines. These plans are now available (online Appendix Table 1, available from http://www.cdc.gov/ncidod/EID/vol12no09/06-0369_appTl.htm). Because state health departments are autonomous of federal control, their approaches to surveillance and containment are likely to vary. Thus, this review was undertaken to determine the extent of differences between states in their approaches to detecting and controlling pandemic influenza.
State Procedures and Plans
Forty-nine states have Internet websites that include statewide pandemic influenza procedures and plans or, in a few instances, have simply addressed broad questions about state-based responses to pandemic influenza (Appendix Table 1). Often these plans, which are funded by a Centers for Disease Control and Prevention (CDC) preparedness cooperative agreement, were posted in the last half of 2005 or early 2006, and these documents are still largely in transition. US HHS has recently issued guidelines (1); however, specific planning, problem solving, and funding are still left to the individual states.
Almost all of the states' plans address a wide range of issues regarding command and control, surveillance, vaccination, antiviral drugs, communication, and emergency management and containment measures. The purpose of this review was to focus on community public health strategies, especially vaccination, surveillance and detection, and containment, which the various states develop as they refine their plans.
In general, all 49 states with posted plans are in accordance with one another on vaccination priority strategies (online Appendix Table 2, available from http://www.cdc.gov/ncidod/EID/vol 12no09/06-0369_appT2.htm). Many state plans indicated that they were constrained by the uncertainties of future vaccine and antiviral drug supply and effectiveness and the properties of a future influenza epidemic.
Nonetheless, general agreement exists, explicit or implicit, to provide vaccination during a pandemic that is prioritized by those most likely to acquire, become ill, or die from pandemic influenza (Appendix Table 2). Generally, these guidelines were based on Advisory Committee on Immunization Practices (ACIP) recommendations (2) and HHS guidelines (1) if the latter were available at the time the state plan was drafted. The clear priorities involved the following groups: 1) healthcare workers (some states also include emergency responders such as emergency medical technicians, fire fighters, and police officers; political leaders; utility workers; transporters of vaccine; and vaccine manufacturers); 2) persons with respiratory, immunodeficiency, cardiovascular or other high-risk conditions; 3) persons >65 years of age (17 [35%] plans also consider vaccinating children 6-23 months of age); 4) household members, caregivers, and other close contacts of those ill or likely to be ill; and 5) all others.
The first 3 of the these groups were variously prioritized by the states as high-priority vaccine recipients, but all states consider these 3 groups as the highest priority. A few states, such as Maine, have estimated that 15%-20% of their populations would be in such high-priority groups to be vaccinated.
Surveillance and Detection
Of the 49 states that have posted their plans, all rely on the National Sentinel Physician Surveillance (NSPS), the nationwide 122 Cities Mortality Reporting System of pneumonia- and influenza-related deaths (3,4), or both. Forty-seven (96%) states also explicitly indicated they would evaluate reports of clusters or unusual influenzalike cases by local physicians, clinics, and institutions in their state, and 40 states (82%) indicated they would evaluate reports of laboratory-confirmed influenza from state health department and other laboratories (Appendix Table 2).
Although many states describe plans for enhanced surveillance during pandemic influenza, relatively few (12 [25%]) currently have or envision real-time syndromic surveillance of influenzalike illness (ILI) in persons seeking care at clinics or hospital emergency departments to detect the onset of pandemic influenza (Appendix Table 2). To our knowledge, the cities currently using syndromic surveillance are New York City, Washington, DC, Pittsburgh, and some cities in North Carolina and Virginia. In addition, the CDC BioSense program (5) plans to expand syndromic surveillance to 300 clinical sites by the end of 2006.
Eight states (16%), including California (especially in Los Angeles), New York, and Hawaii, are developing ways of screening incoming international travelers. However, current plans for other international entry points, such as Seattle, Portland, Chicago, and Atlanta, do not indicate any similar (foreign) international traveler quarantine and testing activities.
The various state plans are markedly heterogeneous in their personal contact-avoidance measures and prophylaxis (Appendix Table 2). Most states outline pandemic influenza responses that do not include general and early encouragement of many specific personal avoidance steps, such as staying home from work and keeping sick children at home.
Seventeen (35%) states explicitly plan or are considering recommending (voluntary) personal social isolation on the community level, such as staying at home or keeping children at home if they feel sick. Eighteen (37%) other states cite federal or state regulations that indicate that health authorities may close schools, businesses, and other institutions during a severe outbreak, although they are not required to resort to such closures. However, 15 (31%) other states also indicate legal ability to quarantine persons, households, or institutions. (However, in some states such as Michigan, the efficacy of quarantine is directly questioned in their current document.)
Given the high cost and limited supply of neuraminidase inhibitor antiviral drugs and an uncertain supply and effectiveness of future vaccines, only 12 (25%) states plan or consider using either chemoprophylaxis (such as oseltamivir) or vaccination of household and other close nonhospital contacts in their plans to retard epidemic influenza.
The control of future pandemic or interpandemic influenza will necessarily rely on each individual state's plan to vaccinate persons and detect and contain this disease. Still, the current national (HHS) pandemic influenza plan presents only a categorization and listing of steps, rather than explicit direction for the states. This lack of central coordination can result in a patchwork of plans that will not adequately detect and control this or other respiratory disease pandemics.
Given the lack of clear guidance, coupled with the fact that no one knows when an influenza pandemic may strike, what its characteristics will be, and the effectiveness and quantity of strain-specific vaccine, the evolving state plans are nonetheless in agreement in adhering generally to ACIP and HHS guidelines for prioritizing vaccination (1,2). In general, the elderly, those with chronic diseases, and healthcare and infrastructure personnel will be prioritized to receive vaccination, and in approximately one third of states, young children will be prioritized to be vaccinated (6). We believe the estimate that such persons make up = 15%-20% of the population in any state is reasonable (1). However, this vaccination strategy is predicated on preventing deaths from influenza, not stopping or retarding an epidemic or pandemic (7). Given that vaccine adequate to cover the entire US population will not be available for several more years, the goal of reducing transmission would require much more vaccination than is available.
Regarding surveillance and detection, state plans are even more variable than they are about strategizing vaccinations. All states indicate that they plan to use the NSPS network and the nationwide 122 Cities Mortality Reporting System (3,4). In NSPS, each year =1,100 (55%) of = 2,000 healthcare providers nationwide voluntarily report the number of weekly outpatient visits for ILI and submit specimens from a subset of patients to state public health laboratories for influenza virus testing. The 122 city-specific mortality reporting is unavoidably even more delayed. Neither system would likely detect a local outbreak of influenza <2 weeks into its establishment. Thus, some state and federal authorities are assessing the utility of syndromic surveillance of ILI (e.g., cough, headache, and fever) in emergency departments and clinics in test cities. Several such programs exist, and CDC's BioSense (5) includes plans to expand such early surveillance to 300 clinical sites. However, to our knowledge, no health authority feels confident that earlier detection of influenza by 1 to 3 weeks would necessarily lead to better control or substantial retardation of an outbreak.
Finally, confusion and lack of specificity exist in these posted state plans in proposing practical containment measures in the community. The national HHS Pandemic Influenza Plan (1) has several recommendations for infection control in the hospital setting but is weaker and nonspecific in other areas such as control of influenza in the community. For example, there is no agreed-upon definition of geographic clustering of cases or number of persons infected that will trigger the declaration of a pandemic. Much of this national plan suggests social distancing and respiratory (cough) etiquette and devotes much of its discussion to mask use. Accordingly, states are comparably nonspecific about community control plans. Vaccination or chemoprophylaxis of contacts is infrequently addressed, mainly because the vaccine supply is limited, as are the most effective antiviral drugs, the neuraminidase inhibitors oseltamivir and zanamivir, for the next several years. Even when these vaccines and drugs become available, considerable obstacles remain to detecting influenza promptly and getting vaccination or drug therapy to the contacts of influenza patients.
Several practical nonpharmaceutical containment steps need to be considered. For example, only approximately one third of the state plans are explicitly considering recommending self-isolation of adults with influenzalike symptoms and keeping children with such symptoms home from school and daycare. Even in this increasingly computer-based economy, in which a considerable percentage of persons can work from home most of the time, this simple stratagem is not addressed in most state plans. Other simple recommendations for use in the community, such as avoiding mass gatherings; shopping on off hours; and household and workplace strategies such as frequent hand washing, avoiding handshaking, and keeping towels separate, are often neglected in state plans.
Why are there these state plans so disparate? We believe some of the problem results from weak central (federal) direction, as has been a criticism of national bioterrorism preparedness (8). Fortunately, state and federal plans are still in flux, many are still in draft form (Appendix Table 1), and getting a clearer delineation of a basic plan that all states can follow is still possible. The US Secretary of HHS has been meeting with states (http://www.pandemieflu.gov/plan/convening.html) to review pandemic preparedness issues.
However, we also believe that answers are lacking to several key epidemiologic questions necessary for rational planning. What is the typical intrahousehold or institutional attack rate, and would vaccination or chemoprophylaxis of contacts retard or stem outbreaks? How well do masks work for pandemic influenza in the community, and when and for how long should they be used? Does closing a school or other institution actually reduce community-level illness and death? Does earlier detection of influenza in a community lead to behavior changes that could stem an outbreak? We know of no studies designed to address these and several other issues; e.g., the Models of Infectious Disease Agents Study (MIDAS) (9) has been forced to rely on estimates of household attack rates estimated >30 years ago (10,11) for a nonpandemic (H3N2) strain of influenza virus. Several state plans, such as California's, expressed frustration about this lack of information.
Thus, we believe that a revision of the national pandemic influenza plan, which despite unavoidable gaps in our knowledge, relies on professional and public health opinion to provide more uniform, specific, and practical influenza protection, avoidance and containment practices for pandemic and interpandemic influenza in the community would be helpful. We also believe it would be prudent to begin studies and, in the interim, create expert panels to determine if masks, school closings, social isolation, and several other nonpharmaceutical strategies would be useful in reducing the illness and death caused by pandemic influenza and its spread in the community.
This work was supported by contract 1 U01 GM070698 from the National Institute of General Medical Sciences, National Institutes of Health (Pilot Projects for MIDAS).
(1.) US Department of Health and Human Services. Pandemic influenza plan. 2005 Nov 4 [cited 2006 Jun 19]. Available from http://www.hhs.gov/pandemicflu/plan/
(2.) Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003;52:1-34.
(3.) Centers for Disease Control and Prevention. Weekly report: influenza summary. [cited 2006 Jun 19]. Available from www.cdc.gov/ncidod/diseases/flu/weekly.htm
(4.) Centers for Disease Control and Prevention (CDC). 121 Cities Mortality Reporting System. 2005 Oct 14. [cited 2006 Jun 19]. Available from www.cdc.gov/epo/dphsi/121hist.htm
(5.) Loonsk JW. Biosens--a national initiative for early detection and quantification of public health emergencies. MMWR Morb Mortal Wkly Rep. 2004;53(Suppl):53-5.
(6.) Longini IM, Halloran ME. Strategy for distribution of influenza vaccine in high-risk groups and children. Am J Epidemiol. 2005;161:303-6.
(7.) Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-86.
(8.) US General Accounting Office. Report to congressional committees. Bioterrorism. Preparedness varied across state and local jurisdictions. 2003 Apr. [cited 2006 Jun 19]. Available from www.gao.gov/cgibin/getrpt?GAO-03-373
(9.) National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). Models of infectious disease agent study (MIDAS). Last update 2006 Jun 19. [cited 2006 Jun 19]. Available from www.nigms.nih.gov/Initiatives/MIDAS
(10.) Elveback L, Ackerman E, Gatewood L, Fox JP. Stochastic two-agent epidemic simulation models for a community of families. Am J Epidemiol. 1971;93:267-80.
(11.) Elveback L, Varma A. Simulation of mathematical models for public health problems. Public Health Rep. 1965;80:106-86.
Scott D. Holmberg, * Christine M. Layton, ([dagger]) George S. Ghneim, ([dagger]) and Diane K. Wagener ([double dagger])
* Research Triangle Institute International, Atlanta, Georgia, USA; ([dagger]) Research Triangle Institute International, Research Triangle Park, North Carolina, USA; and ([double dagger]) Research Triangle Institute International, Washington DC, USA
Dr Holmberg was the chief of the Clinical Epidemiology Section, Division of HIV/AIDS, CDC, between 1986 and 2005. Since 2005, he has been the senior infectious disease epidemiologist at Research Triangle Institute International and a member of the informatics group of MIDAS, funded by the National Institutes of Health. His current main research interests are HIV and influenza epidemiology and prevention.
Address for correspondence: Scott D. Holmberg, Research Triangle Institute International, Koger Center, Oxford Bldg, Ste 119, 2951 Flowers Rd South, Atlanta, GA 30341-5533, USA; email: email@example.com
|Printer friendly Cite/link Email Feedback|
|Author:||Wagener, Diane K.|
|Publication:||Emerging Infectious Diseases|
|Article Type:||Disease/Disorder overview|
|Date:||Sep 1, 2006|
|Previous Article:||Differentiation of tuberculosis strains in a population with mainly Beijing-family strains.|
|Next Article:||Human bocavirus infection among children, Jordan.|